Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
SWOG Cancer Research Network
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07578116CT.gov Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis | — | Not Yet Recruiting | — | — | — |
NCT07610720CT.gov Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT07528898CT.gov Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. | — | Not Yet Recruiting | — | — | — |
NCT07528716CT.gov Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy | — | Not Yet Recruiting | — | — | — |
NCT07527806CT.gov Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging | — | Not Yet Recruiting | — | — | — |
NCT07193394CT.gov Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT07366840CT.gov RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure | — | Not Yet Recruiting | — | — | — |
NCT07299890CT.gov An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07307287CT.gov SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study | — | Not Yet Recruiting | — | — | — |
NCT07246317CT.gov Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer | — | Not Yet Recruiting | — | — | — |
Show 412 more trialsShow fewer
NCT07245797CT.gov A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC | — | Not Yet Recruiting | — | — | — |
NCT07007559CT.gov ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer | — | Recruiting | — | — | — |
NCT07216105CT.gov FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07407920CT.gov Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial | — | Active Not Recruiting | — | — | — |
NCT07102381CT.gov A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | — | Recruiting | — | — | — |
NCT07136974CT.gov Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer. | — | Not Yet Recruiting | — | — | — |
NCT07095023CT.gov Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | — | Recruiting | — | — | — |
NCT07047443CT.gov SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression | — | Not Yet Recruiting | — | — | — |
NCT07003074CT.gov A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06927180CT.gov SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC | — | Recruiting | — | — | — |
NCT06686394CT.gov Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | — | Recruiting | — | — | — |
NCT07615751CT.gov Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer | — | Recruiting | — | — | — |
NCT06038539CT.gov Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer | — | Terminated | — | — | — |
NCT06625775CT.gov Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06649331CT.gov Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05933395CT.gov Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor | — | Recruiting | — | — | — |
NCT07386938CT.gov A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06439693CT.gov The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06510465CT.gov Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA) | — | Not Yet Recruiting | — | — | — |
NCT06483386CT.gov Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06324357CT.gov Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | — | Recruiting | — | — | — |
NCT05919108CT.gov Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | — | Recruiting | — | — | — |
NCT06362096CT.gov A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer | — | Unknown | — | — | — |
NCT06239467CT.gov First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT07335081CT.gov ctDNA in HER2+ EBC Neoadjuvant Treatment | — | Recruiting | — | — | — |
NCT05458674CT.gov Tucatinib+Trastuzumab+Eribulin in HER2+ MBC | — | Recruiting | — | — | — |
NCT06217185CT.gov The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | — | Recruiting | — | — | — |
NCT06254690CT.gov The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study | — | Recruiting | — | — | — |
NCT06162559CT.gov Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study | — | Recruiting | — | — | — |
NCT06100874CT.gov A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) | — | Active Not Recruiting | — | — | — |
NCT05900206CT.gov Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer | — | Recruiting | — | — | — |
NCT05894239CT.gov A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05983094CT.gov Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06035679CT.gov Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | — | Recruiting | — | — | — |
NCT04901299CT.gov Fulvestrant + Neratinib In Breast Cancer | — | Withdrawn | — | — | — |
NCT05332561CT.gov Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | — | Recruiting | — | — | — |
NCT07416409CT.gov Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer | — | Completed | — | — | — |
NCT05256745CT.gov RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer | — | Recruiting | — | — | — |
NCT06000917CT.gov A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer | — | Recruiting | — | — | — |
NCT05841381CT.gov Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05918328CT.gov Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC | — | Recruiting | — | — | — |
NCT05020860CT.gov Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | — | Recruiting | — | — | — |
NCT05430347CT.gov Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer | — | Unknown | — | — | — |
NCT05323955CT.gov Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib | — | Active Not Recruiting | — | — | — |
NCT05760612CT.gov Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab | — | Recruiting | — | — | — |
NCT04789096CT.gov Tucatinib Together With Pembrolizumab and Trastuzumab | — | Terminated | — | — | — |
NCT05238831CT.gov SMMART Adaptive Clinical Treatment (ACT) Trial | — | Withdrawn | — | — | — |
NCT05376878CT.gov An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis | — | Recruiting | — | — | — |
NCT05638594CT.gov Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer | — | Recruiting | — | — | — |
NCT05388149CT.gov Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | — | Recruiting | — | — | — |
NCT05659056CT.gov Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer | — | Unknown | — | — | — |
NCT05582499CT.gov Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | — | Recruiting | — | — | — |
NCT05577923CT.gov Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower) | — | Unknown | — | — | — |
NCT05572645CT.gov Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab | — | Completed | — | — | — |
NCT05491057CT.gov Treatment Patterns of Neratinib in HER2+ EBC in China | — | Not Yet Recruiting | — | — | — |
NCT05885776CT.gov Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research | — | Unknown | — | — | — |
NCT05574881CT.gov Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT04997798CT.gov Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer | — | Unknown | — | — | — |
NCT05252988CT.gov Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib | — | Active Not Recruiting | — | — | — |
NCT05243641CT.gov Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test | — | Terminated | — | — | — |
NCT05800756CT.gov Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer | — | Unknown | — | — | — |
NCT04886531CT.gov Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | — | Recruiting | — | — | — |
NCT05296798CT.gov A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | — | Active Not Recruiting | — | — | — |
NCT05415215CT.gov A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT04512261CT.gov TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases | — | Withdrawn | — | — | — |
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04329065CT.gov Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer | — | Recruiting | — | — | — |
NCT05319873CT.gov Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05131893CT.gov Neoadjuvant Treatment of Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05180006CT.gov Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy | — | Terminated | — | — | — |
NCT05228951CT.gov Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC | — | Recruiting | — | — | — |
NCT05143970CT.gov A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05159193CT.gov Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer | — | Recruiting | — | — | — |
NCT05041842CT.gov Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04856475CT.gov Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer | — | Withdrawn | — | — | — |
NCT05113251CT.gov Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05346861CT.gov Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab | — | Unknown | — | — | — |
NCT05063786CT.gov Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | — | Active Not Recruiting | — | — | — |
NCT04383275CT.gov Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS) | — | Recruiting | — | — | — |
NCT05020964CT.gov Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib | — | Unknown | — | — | — |
NCT04733118CT.gov Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04973319CT.gov Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy | — | Not Yet Recruiting | — | — | — |
NCT05292742CT.gov Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer | — | Recruiting | — | — | — |
NCT04922008CT.gov Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D) | — | Not Yet Recruiting | — | — | — |
NCT04680442CT.gov Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction | — | Recruiting | — | — | — |
NCT05656079CT.gov To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study | — | Unknown | — | — | — |
NCT04893109CT.gov ATEMPT 2.0: Adjuvant T-DM1 vs TH | — | Recruiting | — | — | — |
NCT04717531CT.gov Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer | — | Unknown | — | — | — |
NCT04108858CT.gov Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer | — | Terminated | — | — | — |
NCT04873362CT.gov A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | — | Active Not Recruiting | — | — | — |
NCT04858516CT.gov Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer | — | Unknown | — | — | — |
NCT04721977CT.gov A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) | — | Active Not Recruiting | — | — | — |
NCT04307329CT.gov Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial | — | Completed | — | — | — |
NCT04759248CT.gov Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04569747CT.gov A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04639271CT.gov Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis | — | Unknown | — | — | — |
NCT06907082CT.gov Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice | — | Completed | — | — | — |
NCT04334330CT.gov Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China | — | Unknown | — | — | — |
NCT04683445CT.gov Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer | — | Unknown | — | — | — |
NCT04917900CT.gov Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer | — | Unknown | — | — | — |
NCT04629846CT.gov Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. | — | Completed | — | — | — |
NCT04591431CT.gov The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | — | Unknown | — | — | — |
NCT04509596CT.gov DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer | — | Completed | — | — | — |
NCT03988036CT.gov A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) | — | Completed | — | — | — |
NCT04425018CT.gov MARGetuximab Or Trastuzumab (MARGOT) | — | Active Not Recruiting | — | — | — |
NCT03820141CT.gov Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03846583CT.gov Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | — | Withdrawn | — | — | — |
NCT04367090CT.gov Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer | — | Completed | — | — | — |
NCT05629949CT.gov A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT04120246CT.gov Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | — | Suspended | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04266249CT.gov CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | — | Active Not Recruiting | — | — | — |
NCT04290793CT.gov Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04253561CT.gov Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients | — | Completed | — | — | — |
NCT04158258CT.gov A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America | — | Active Not Recruiting | — | — | — |
NCT04197687CT.gov TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | — | Unknown | — | — | — |
NCT04215003CT.gov A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC | — | Recruiting | — | — | — |
NCT04236310CT.gov A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. | — | Unknown | — | — | — |
NCT04262804CT.gov A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | — | Unknown | — | — | — |
NCT05346107CT.gov PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer | — | Unknown | — | — | — |
NCT04246502CT.gov Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT04188548CT.gov A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | — | Active Not Recruiting | — | — | — |
NCT03698383CT.gov Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT04905667CT.gov Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ® | — | Completed | — | — | — |
NCT04088110CT.gov Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer | — | Unknown | — | — | — |
NCT04152057CT.gov Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer | — | Unknown | — | — | — |
NCT03994107CT.gov Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer | — | Unknown | — | — | — |
NCT04066790CT.gov Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | — | Terminated | — | — | — |
NCT03368729CT.gov Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04109391CT.gov Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 | — | Completed | — | — | — |
NCT03756064CT.gov Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer | — | Unknown | — | — | — |
NCT03812393CT.gov Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast | — | Unknown | — | — | — |
NCT03913234CT.gov Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients | — | Unknown | — | — | — |
NCT03910712CT.gov Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC | — | Unknown | — | — | — |
NCT05301530CT.gov Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. | — | Completed | — | — | — |
NCT03894007CT.gov Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer | — | Terminated | — | — | — |
NCT03742986CT.gov Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) | — | Completed | — | — | — |
NCT03931551CT.gov Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer | — | Terminated | — | — | — |
NCT03863223CT.gov A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT03644186CT.gov To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) | — | Completed | — | — | — |
NCT03199885CT.gov Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT04102618CT.gov A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | — | Terminated | — | — | — |
NCT03765983CT.gov GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases | — | Terminated | — | — | — |
NCT03501979CT.gov Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | — | Terminated | — | — | — |
NCT03747120CT.gov Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] | — | Active Not Recruiting | — | — | — |
NCT03726879CT.gov A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | — | Completed | — | — | — |
NCT04172259CT.gov ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | — | Active Not Recruiting | — | — | — |
NCT03767335CT.gov MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03433313CT.gov Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer | — | Completed | — | — | — |
NCT06190600CT.gov Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy | — | Active Not Recruiting | — | — | — |
NCT03094052CT.gov Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | — | Completed | — | — | — |
NCT03523585CT.gov DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | — | Completed | — | — | — |
NCT03556358CT.gov Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | — | Completed | — | — | — |
NCT03414658CT.gov The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03493854CT.gov A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer | — | Completed | — | — | — |
NCT03432741CT.gov Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT03101748CT.gov Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT05301010CT.gov Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients | — | Completed | — | — | — |
NCT03321981CT.gov MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. | — | Completed | — | — | — |
NCT03377387CT.gov Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03379428CT.gov Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03321045CT.gov Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness | — | Recruiting | — | — | — |
NCT03364348CT.gov 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT03289039CT.gov Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03095352CT.gov Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease | — | Completed | — | — | — |
NCT03264547CT.gov A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab | — | Completed | — | — | — |
NCT03179904CT.gov TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03135171CT.gov Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab | — | Completed | — | — | — |
NCT05765357CT.gov Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers | — | Completed | — | — | — |
NCT02907918CT.gov Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer | — | Terminated | — | — | — |
NCT03161353CT.gov Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. | — | Active Not Recruiting | — | — | — |
NCT03112590CT.gov Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | — | Completed | — | — | — |
NCT03182634CT.gov The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial | — | Unknown | — | — | — |
NCT03006172CT.gov To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02673398CT.gov Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT03144947CT.gov Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients | — | Unknown | — | — | — |
NCT02789657CT.gov Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. | — | Completed | — | — | — |
NCT03084237CT.gov Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03273595CT.gov Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer | — | Unknown | — | — | — |
NCT02843126CT.gov Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer | — | Completed | — | — | — |
NCT02649686CT.gov Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab | — | Completed | — | — | — |
NCT02624973CT.gov PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial | — | Active Not Recruiting | — | — | — |
NCT03006614CT.gov PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer | — | Unknown | — | — | — |
NCT02657343CT.gov An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. | — | Completed | — | — | — |
NCT02605915CT.gov Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer | — | Completed | — | — | — |
NCT02627274CT.gov A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) | — | Completed | — | — | — |
NCT02569489CT.gov Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer | — | Withdrawn | — | — | — |
NCT02562378CT.gov T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02344472CT.gov Detect V / CHEVENDO (Chemo vs. Endo) | — | Active Not Recruiting | — | — | — |
NCT02448420CT.gov Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02402712CT.gov Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer | — | Completed | — | — | — |
NCT02390427CT.gov Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer | — | Completed | — | — | — |
NCT02393248CT.gov Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | — | Terminated | — | — | — |
NCT02226276CT.gov Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02339532CT.gov Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status | — | Completed | — | — | — |
NCT02260531CT.gov Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases | — | Completed | — | — | — |
NCT02238509CT.gov Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies | — | Unknown | — | — | — |
NCT02213042CT.gov Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT02297698CT.gov Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients | — | Completed | — | — | — |
NCT02318901CT.gov Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | — | Terminated | — | — | — |
NCT02187744CT.gov A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | — | Completed | — | — | — |
NCT02091960CT.gov A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT02236000CT.gov A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT02152943CT.gov Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | — | Completed | — | — | — |
NCT02213744CT.gov MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | — | Terminated | — | — | — |
NCT02167854CT.gov Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer | — | Completed | — | — | — |
NCT02336984CT.gov A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | — | Withdrawn | — | — | — |
NCT02144012CT.gov A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer | — | Terminated | — | — | — |
NCT02066532CT.gov Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | — | Completed | — | — | — |
NCT02000882CT.gov STAR Cape+BKM120 MBC With Brain Met | — | Completed | — | — | — |
NCT02060253CT.gov Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | — | Completed | — | — | — |
NCT01989676CT.gov A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) | — | Completed | — | — | — |
NCT01964391CT.gov A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer | — | Completed | — | — | — |
NCT02003209CT.gov Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT02065609CT.gov 89ZrTrastuzumab Breast Imaging With Positron Emission Tomography | — | Completed | — | — | — |
NCT02073487CT.gov Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel | — | Completed | — | — | — |
NCT01966471CT.gov A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | — | Completed | — | — | — |
NCT02000596CT.gov 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. | — | Terminated | — | — | — |
NCT02030561CT.gov NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer | — | Unknown | — | — | — |
NCT01996267CT.gov Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 | — | Active Not Recruiting | — | — | — |
NCT02059876CT.gov Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer | — | Unknown | — | — | — |
NCT01973660CT.gov PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer | — | Completed | — | — | — |
NCT00397501CT.gov BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain | — | Withdrawn | — | — | — |
NCT01875367CT.gov Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer | — | Completed | — | — | — |
NCT01950182CT.gov Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer | — | Completed | — | — | — |
NCT01985893CT.gov Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT01928615CT.gov A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer | — | Terminated | — | — | — |
NCT01912963CT.gov Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | — | Terminated | — | — | — |
NCT01873833CT.gov Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01730833CT.gov Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | — | Completed | — | — | — |
NCT01597414CT.gov Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 | — | Completed | — | — | — |
NCT01570036CT.gov Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | — | Completed | — | — | — |
NCT01853748CT.gov T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) | — | Completed | — | — | — |
NCT01901146CT.gov Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer | — | Completed | — | — | — |
NCT01772472CT.gov A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) | — | Completed | — | — | — |
NCT01832051CT.gov Clinical Value of 89Zr-trastuzumab PET | — | Completed | — | — | — |
NCT01479179CT.gov Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab | — | Withdrawn | — | — | — |
NCT01705340CT.gov Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | — | Terminated | — | — | — |
NCT01679743CT.gov GRN1005 for Brain Metastases From Breast or Lung Cancer | — | Withdrawn | — | — | — |
NCT02472964CT.gov Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. | — | Completed | — | — | — |
NCT01688609CT.gov Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer | — | Completed | — | — | — |
NCT01526369CT.gov A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01471847CT.gov A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab | — | Completed | — | — | — |
NCT01434303CT.gov Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only | — | Completed | — | — | — |
NCT01290718CT.gov A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy. | — | Terminated | — | — | — |
NCT01503905CT.gov Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients | — | Unknown | — | — | — |
NCT04175171CT.gov Clinical Trial of Comparative Study of GB221 Pharmacokinetics | — | Completed | — | — | — |
NCT01512199CT.gov Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) | — | Terminated | — | — | — |
NCT01501487CT.gov MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I | — | Completed | — | — | — |
NCT01480583CT.gov GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases | — | Completed | — | — | — |
NCT01432886CT.gov A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer | — | Completed | — | — | — |
NCT01137994CT.gov A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT00999804CT.gov Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy | — | Active Not Recruiting | — | — | — |
NCT01401959CT.gov Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy | — | Completed | — | — | — |
NCT01300962CT.gov Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01386580CT.gov An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | — | Completed | — | — | — |
NCT01306942CT.gov Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | — | Completed | — | — | — |
NCT01367028CT.gov A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer | — | Completed | — | — | — |
NCT01160211CT.gov A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01423123CT.gov Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer | — | Completed | — | — | — |
NCT01220128CT.gov Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | — | Terminated | — | — | — |
NCT00964704CT.gov A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT01304797CT.gov Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer | — | Unknown | — | — | — |
NCT01276041CT.gov Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT01205217CT.gov Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer | — | Withdrawn | — | — | — |
NCT01008150CT.gov Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | — | Completed | — | — | — |
NCT01485926CT.gov A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients. | — | Completed | — | — | — |
NCT01254136CT.gov Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer | — | Terminated | — | — | — |
NCT01120184CT.gov A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | — | Completed | — | — | — |
NCT01084876CT.gov Demonstrate Efficacy and Safety of Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01132664CT.gov Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer | — | Terminated | — | — | — |
NCT01387373CT.gov Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer | — | Completed | — | — | — |
NCT01104571CT.gov Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer | — | Unknown | — | — | — |
NCT01387295CT.gov Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease | — | Completed | — | — | — |
NCT01111825CT.gov Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT01042379CT.gov I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | — | Recruiting | — | — | — |
NCT01084863CT.gov Evaluate Safety, Efficacy and Pharmacokinetics | — | Completed | — | — | — |
NCT01042925CT.gov Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | — | Completed | — | — | — |
NCT01104935CT.gov National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT] | — | Completed | — | — | — |
NCT01007942CT.gov Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00963547CT.gov A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) | — | Terminated | — | — | — |
NCT00876395CT.gov Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00915018CT.gov Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer | — | Completed | — | — | — |
NCT00885755CT.gov A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00960960CT.gov A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01321775CT.gov Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer | — | Unknown | — | — | — |
NCT01170143CT.gov Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer | — | Unknown | — | — | — |
NCT00878709CT.gov Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | — | Completed | — | — | — |
NCT00788333CT.gov Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer | — | Completed | — | — | — |
NCT00971737CT.gov Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00928330CT.gov Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy | — | Completed | — | — | — |
NCT00912340CT.gov Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00769470CT.gov Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery | — | Completed | — | — | — |
NCT00807859CT.gov Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00817362CT.gov Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | — | Terminated | — | — | — |
NCT00770809CT.gov Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery | — | Completed | — | — | — |
NCT00777101CT.gov Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | — | Completed | — | — | — |
NCT00820872CT.gov Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer | — | Completed | — | — | — |
NCT00842998CT.gov Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer | — | Unknown | — | — | — |
NCT00841828CT.gov Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | — | Completed | — | — | — |
NCT00824733CT.gov Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00821886CT.gov Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00833963CT.gov A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine | — | Completed | — | — | — |
NCT00741260CT.gov Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | — | Completed | — | — | — |
NCT00788931CT.gov A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00847171CT.gov Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00811135CT.gov A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT00712881CT.gov Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT00667251CT.gov Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00717405CT.gov A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer. | — | Completed | — | — | — |
NCT00768859CT.gov Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study | — | Completed | — | — | — |
NCT00795678CT.gov Chemotherapeutic Agents in Brain/Breast | — | Completed | — | — | — |
NCT00679341CT.gov A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease | — | Completed | — | — | — |
NCT00736970CT.gov Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009) | — | Completed | — | — | — |
NCT00548184CT.gov Lapatinib and Trastuzumab With or Without Endocrine Therapy | — | Completed | — | — | — |
NCT00708903CT.gov Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization) | — | Completed | — | — | — |
NCT00847366CT.gov Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma | — | Completed | — | — | — |
NCT00706030CT.gov Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00567879CT.gov A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab | — | Terminated | — | — | — |
NCT00503750CT.gov Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™) | — | Completed | — | — | — |
NCT00674414CT.gov Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery | — | Terminated | — | — | — |
NCT00618657CT.gov Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | — | Completed | — | — | — |
NCT00490646CT.gov A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00553358CT.gov Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study | — | Completed | — | — | — |
NCT03014076CT.gov Immunotherapy Vaccine and Herceptin in Breast Cancer | — | Completed | — | — | — |
NCT00574587CT.gov Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | — | Completed | — | — | — |
NCT00412412CT.gov CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study | — | Completed | — | — | — |
NCT00567554CT.gov Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer | — | Completed | — | — | — |
NCT00434031CT.gov CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer | — | Withdrawn | — | — | — |
NCT00524303CT.gov Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. | — | Completed | — | — | — |
NCT00864175CT.gov Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00426556CT.gov Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00535509CT.gov Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00493649CT.gov Adj TC + Herceptin Early Stage Breast Cancer | — | Completed | — | — | — |
NCT00490139CT.gov ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D | — | Completed | — | — | — |
NCT00470704CT.gov Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00398567CT.gov A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00470847CT.gov Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT00458237CT.gov Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00436566CT.gov Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery | — | Completed | — | — | — |
NCT00482391CT.gov Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer | — | Completed | — | — | — |
NCT00532857CT.gov Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab | — | Completed | — | — | — |
NCT00450892CT.gov Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer | — | Completed | — | — | — |
NCT00367471CT.gov Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer. | — | Completed | — | — | — |
NCT00411788CT.gov A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00372424CT.gov Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive | — | Completed | — | — | — |
NCT00388726CT.gov E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00387907CT.gov Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00404066CT.gov Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer | — | Completed | — | — | — |
NCT00398489CT.gov Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | — | Unknown | — | — | — |
NCT00391092CT.gov A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. | — | Completed | — | — | — |
NCT00429299CT.gov Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer | — | Completed | — | — | — |
NCT00258349CT.gov Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer | — | Completed | — | — | — |
NCT00377780CT.gov Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00365365CT.gov Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer | — | Completed | — | — | — |
NCT00367250CT.gov Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00407888CT.gov Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery | — | Completed | — | — | — |
NCT00317720CT.gov Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer | — | Completed | — | — | — |
NCT00258960CT.gov Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00331552CT.gov Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00284180CT.gov Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00803556CT.gov Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy | — | Completed | — | — | — |
NCT00272987CT.gov ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | — | Terminated | — | — | — |
NCT00266110CT.gov Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00303108CT.gov Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00320385CT.gov Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00254592CT.gov Neoadjuvant Treatment of Breast Cancer | — | Completed | — | — | — |
NCT00246090CT.gov A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine | — | Completed | — | — | — |
NCT00301730CT.gov Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung | — | Completed | — | — | — |
NCT00251433CT.gov GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00232479CT.gov Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer | — | Completed | — | — | — |
NCT00127933CT.gov XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer | — | Completed | — | — | — |
NCT00140140CT.gov A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer | — | Terminated | — | — | — |
NCT00182793CT.gov Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00238290CT.gov Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer | — | Completed | — | — | — |
NCT00077376CT.gov Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00216047CT.gov PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00093145CT.gov Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00337649CT.gov A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00256243CT.gov Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer | — | Completed | — | — | — |
NCT00085020CT.gov GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu | — | Completed | — | — | — |
NCT00129896CT.gov Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients | — | Completed | — | — | — |
NCT00079326CT.gov Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00088985CT.gov Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00086957CT.gov Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00148668CT.gov Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer | — | Completed | — | — | — |
NCT00250874CT.gov Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00068757CT.gov Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00095706CT.gov Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF) | — | Completed | — | — | — |
NCT00171847CT.gov Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00054470CT.gov Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT00429104CT.gov Herceptin and GM-CSF for Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00169104CT.gov Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function | — | Terminated | — | — | — |
NCT00039455CT.gov Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00024154CT.gov Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02748213CT.gov A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00795899CT.gov Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO) | — | Completed | — | — | — |
NCT00028535CT.gov Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors | — | Completed | — | — | — |
NCT00031278CT.gov Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02015676CT.gov A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00148681CT.gov Preoperative Herceptin and Navelbine for Breast Cancer | — | Completed | — | — | — |
NCT00016276CT.gov Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT01423695CT.gov Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00004888CT.gov Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00006123CT.gov Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT00006825CT.gov Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00006228CT.gov Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00006381CT.gov Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00014430CT.gov Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer | — | Completed | — | — | — |
NCT00004935CT.gov Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 | — | Terminated | — | — | — |
NCT00004925CT.gov Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00004074CT.gov Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab (this asset) | SWOG Cancer Research Network | Approved | BB · 69 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Trastuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 76 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 74 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →